论文部分内容阅读
本文描述新的口服非巯基血管紧张素转换酶(ACE)抑制剂 CI—906二次量对8名原发性高血压受试者血压、激素水平影响的研究.以0.625毫克开始,与安慰剂隔日使用,连续用药的病人剂量加倍直至获得全效(约5和10毫克),其余病人接受相同的全效量,所有的剂量包括最小量都引起 ACE 的抑制,同时伴有血浆肾素活性的升高(约为10.9±2.1毫微克),不过,尽管不完全和维持时间短,用2.5毫克就可观察到对血压有临床意义的影响.不论治疗前肾素水平为何,两个最大剂量按平均血压降低的大小(各为26±5和25±2.5mmHg)和持续时间(变动范围从12到24小时以上)而言,产生的效应相似。无体位性低血压、心动过速、或其它不良反应.
This article describes the effects of a second oral non-sulfacanthin (ACE) inhibitor, CI-906, on blood pressure and hormone levels in 8 essential hypertensive subjects starting at 0.625 mg compared with placebo Dosages were repeated on alternate days, doubling the dose of continuous medication until full efficacy was achieved (approximately 5 and 10 mg), the remaining patients received the same full dose and all doses, including minimal amounts, caused the inhibition of ACE accompanied by plasma renin activity (About 10.9 ± 2.1 ng), although, although incomplete and short in duration, a clinically significant effect on blood pressure was observed with 2.5 mg. Regardless of the level of renin prior to treatment, the two maximal doses The mean reduction in blood pressure (26 ± 5 and 25 ± 2.5 mmHg each) and duration (ranging from 12 to 24 hours) produced similar effects. No orthostatic hypotension, tachycardia, or other adverse reactions.